🔴 Citius Pharmaceuticals is trading 5.83% down in pre-market — no company-specific explanation identified

Citius Pharmaceuticals is trading at $0.54, down 5.83% in pre-market, with no identified company-specific catalyst.

• No company-specific announcement explaining the November 4 pre-market decline was identified. The recent LYMPHIR shipment update was reported earlier, not on November 4.
• Broad U.S. futures were modestly higher, while Asian markets fell amid election-related concerns; these mixed signals do not establish a reason for the stock’s decline. Available evidence leaves the move unexplained.